Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Status:
RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Phase:
PHASE4
Details
Lead Sponsor:
Marzieh Salehi
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)